Trial Profile
A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2015
Price :
$35
*
At a glance
- Drugs TMC 649128 (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Janssen Infectious Diseases BVBA
- 13 Feb 2012 Company (Tibotec BVBA) added as trial sponsor as reported by ClinicalTrials.gov record (NCT01532557).
- 13 Feb 2012 Company (Tibotec BVBA) added as trial sponsor as reported by ClinicalTrials.gov record (NCT01532557).
- 16 Nov 2011 Status changed from recruiting to discontinued according to a Medivir media release.